Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?

The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19

(2020) Virginia D. Schmith et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prioritisation of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

(2020) Usman Arshad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

(2020) Ulf Andersson et al.   MOLECULAR MEDICINE

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

(2020) Khan Sharun et al.   Annals of Clinical Microbiology and Antimicrobials

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing

(2020) Brian Jermain et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Anti-inflammatory effects of ivermectin in mouse model of allergic asthma

(2011) Shuhan Yan et al.   INFLAMMATION RESEARCH

Phylogeny and metabolic scaling in mammals

(2010) Isabella Capellini et al.   ECOLOGY

Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway

(2009) Xinxin Ci et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages

(2009) Xuemei Zhang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice

(2008) X. Zhang et al.   INFLAMMATION RESEARCH